Testing

Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebral spinal fluid.

By Samantha Rossi • May 17, 2022

Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.

By Samantha Rossi • May 10, 2022

In April 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Meghann Southwick • May 5, 2022

This list includes updates posted to mayocliniclabs.com during the month of April.

By Michael Hutchison • May 2, 2022

In this “Test in Focus” episode of the  "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.

By Samantha Rossi • April 19, 2022

Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' synovial fluid testing for patients with symptoms of failed hip arthroplasty. The Food and Drug Administration recommends testing for elevated chromium and cobalt, which can indicate a malfunctioning metal hip implant. A Mayo Clinic study found that synovial fluid testing for those elements is more sensitive than serum or whole blood testing.

By Samantha Rossi • April 12, 2022

In March 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Chantell Canfield • April 7, 2022

Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which have associations to thiopurine metabolization.

By Samantha Rossi • April 5, 2022

CPT Code updates posted to mayocliniclabs.com during the month of

By Michael Hutchison • April 1, 2022

Maria Alice Willrich, Ph.D., explains kappa free light chain testing — Mayo Clinic Laboratories' data-driven approach to diagnose multiple sclerosis. The automated assay is more sensitive, cost-effective, and faster than traditional oligoclonal banding, enabling definitive answers for the challenging diagnosis.

By Samantha Rossi • March 29, 2022

Mayo Clinic researchers have developed and validated a new antibody test to diagnose multiple sclerosis (MS). The new test is an automated and cost-effective method compared to other tests used to diagnose MS, according to the research published in Mayo Clinic Proceedings. The test is now available through Mayo Clinic Laboratories.

By Suzanne Ferguson • March 24, 2022

John Lieske, M.D., discusses Mayo Clinic Laboratories' urinary ammonium testing. A test that takes the guesswork out of determining acid base disorders by giving nephrologists a true understanding of a patient’s true urinary ammonium level.

By Samantha Rossi • March 15, 2022

In February 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Chantell Canfield • March 3, 2022